Stella Chemifa CorporationClinical Pharmacology and TherapeuticsChief：Prof. Takafumi NaitoBiocompatible System EngineeringProf. Takeshi Uemura• Development and safety evaluation of innovative biomaterials. • Research on the molecular mechanisms of neural circuit and synapse • Research on the pathogenesis of neurodevelopmental disorders.Our department creates the drug information for implementing therational pharmacotherapy in clinical settings. For the goal, wedevelop the quantitative methods of drugs in human biologicalsamples using a liquid chromatograph coupled to massspectrometer. The present projects quantitatively evaluate the inter-individual variations in clinicalresponses to drugs from theviewpoints of pharmacokinetics and pharmacodynamics. We finallyaim to construct the rational pharmacotherapy based on the factorsrelated to the clinical responses to drugs for each disease and itscondition.Research subjectOutlook for researchOutlook for students after graduationWe are researching in two key areas: brain science and biomaterials,to revolutionize future medicine. Biomaterials are crucial for cancertherapy and regenerative medicine, and we aim to develop new onesby understanding their biological responses. In brain science, we focuson understanding synapses, crucial for neuronal circuit formation andfundamental processes of brain functions such as learning, memory,and emotion. This knowledge could lead to the development of newtreatments for mental disorders. Our goal is to contribute to enhancingpeople's health and advancing the future of medical care.Research subjectOutlook for researchOutlook for students after graduationCerebellar Purkinje cells labeled with fluorescent proteinactive zone protein Bassoonmagnetic beadsPrimary cortical neurons cultured on a substrate with an enhanced surface, co-developed with a company・Development of quantitative methods of drugs in human biological samples・Evaluation of inter-individual variations in clinical responses to drugs・Construction of rational pharmacotherapy for the disease and its conditions・Detection of unknown adverse events and drug-drug interactions using non-experimental methodsClarification of patient factors related to the pharmacokinetics, drug efficacy,and adverse reactions contributes to the individualization of pharmacotherapy.Our achievements lead to the construction of the rational pharmacotherapy forthe disease and its conditions.After receiving an academic degree, a lot of our laboratory graduates work asa clinical pharmacist or researcher. Some graduates can be engaged in thedrug discovery research and development at a pharmaceutical company.formation. There are still numerous diseases for which no cure has been found. Basicknowledge about the brain can be a solid step toward overcoming mentaldisorders in the future. By utilizing insights gained from the mechanisms ofliving organisms, new materials can be developed, offering new approaches todiseases that are currently difficult to treat.After graduation, you can engage in various fields, including research and engineering.Optimization of individual pharmacotherapy based on the multiple evaluation of patient information（Naito T. Biol Pharm Bull 2019;42:149-57）TDM of cetuximab (anti-EGFR antibody) in head and neck cancer patients（Shibata K, et al. Cancer Chemother Pharmacol. 2021;87:555-65）Presynaptic structures induced by magnetic beads immobilized with synaptogenic factor Wild-type mouseKnock-out mouse Electron microscopic images of cerebellum lacking synaptic formation factor35Exploring uncharted territories in neuroscience and biomaterials信州大学医学部医学科発行年月：２０２４年７月 発行：信州大学医学部Creating the drug information for implementing the rational pharmacotherapy in clinical settings
元のページ ../index.html#40